Yadav et al. Bevacizumab and radiation need intact vessels in GBM therapy
NeuroOncology occurs along existing blood vessels through vessel cooption. 5, 6 The existing vasculature is eventually unable to support tumor growth resulting in hypoxia and expression of hypoxia inducible factor 1α (HIF-1α). 7, 8 In response to HIF-1α, gliomas undergo an "angiogenic switch" and increase secretion of pro-angiogenic growth factors. The most important growth factor induced by HIF-1α is vascular endothelial growth factor (VEGF), the expression of which has been shown to correlate with tumor grade and patient survival. 9 Due to its central role in angiogenesis, inhibition of VEGF has been a general strategy for the treatment of glioma. Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF, thus preventing its interaction with VEGF receptors and subsequent angiogenesis. 10 Bevacizumab was approved for recurrent glioma in 2009 after demonstrating increased progression-free survival (PFS) in clinical trials. 11 Despite early promise, 2 large phase III trials involving bevacizumab failed to demonstrate an overall survival (OS) benefit in unselected patient populations compared with standard combination temozolomide and radiation followed by cyclic temozolomide. [12] [13] [14] The impact of bevacizumab on PFS indicates that anti-VEGF therapy is biologically active; however, tumor escape mechanisms may prevent a durable treatment response.
Cellular and molecular mechanisms of resistance to antiangiogenics are not well understood. VEGF-independent mechanisms of angiogenesis may be important contributors to treatment resistance. 15 Glioma patients resistant to anti-VEGF therapy have increased plasma levels of alternative pro-angiogenic factors such as fibroblast growth factor 2, stromal cell derived factor 1, platelet derived growth factor, angiopoietin 1 and 2, and c-Met. 16 Additionally, dual inhibition of VEGF and angiopoietin 2 improved OS in a murine glioma model. 17 Angiogenesis may also occur through migration of bone marrow-derived endothelial precursor cells to the tumor, such as Tie2 positive monocytes and macrophages. 18 Simultaneous targeting of multiple angiogenesis pathways may overcome anti-VEGF treatment resistance.
To understand the role of tumor blood vessel integrity on glioma progression, we studied the effect of inducible genetic ablation of proliferating vascular endothelium on OS in a murine glioma model. We tested the hypothesis that the therapeutic effect of anti-VEGF and radiation therapy in glioma would be potentiated by eliminating cells that contribute to the repair and growth of blood vessels in the brain (ie, vascular endothelial cells and bone marrowderived monocytes).
Our results indicate that killing of cells that contribute to the repair and growth of glioma blood vessels prolonged the survival of Tie2-TK mice implanted with syngeneic glioma cells. To our surprise, however, in our model, disruption of the glioma microvasculature inhibited the antitumor effect of anti-VEGF or radiation. We conclude that, in our model, intact tumor blood vessels are necessary for the long-term effectiveness of antiglioma therapy such as anti-VEGF or irradiation. Clinically, our results suggest that careful consideration ought to be given to the effects of antiglioma drugs, especially when administered concomitantly with irradiation and/or bevacizumab.
Materials and Methods

Animal Strains
Six-to 8-week-old transgenic Tie2p/e LV [Tie2-TK-IRIS-GFP] Friend virus B mice were genetically engineered to conditionally express thymidine kinase specifically within Tie2-expressing cells. These mice were a kind gift from Dr Luigi Naldini (see Supplementary material for details). All animals were maintained and experiments conducted in accordance with the Unit for Laboratory Animal Medicine at the University of Michigan.
Glioblastoma Cell Lines
A primary glioma cell line expressing NRAS and reduced levels of p53 (NP) was generated from a mouse bearing an NP-glial tumor induced by the Sleeping Beauty system 19 (see Supplementary material).
Stereotactic Tumor Implantation and Processing of Tissue Samples
NP neurospheres (1.0 × 10 3 cells in 1 μL) were stereotactically injected into the right striatum of Tie2-TK adult mice, as previously described 20 ; see Supplementary material for details.
Importance of the study
This study addresses the role of proliferating vessel endothelial cells in glioma growth using a transgenic mouse model in which we can ablate proliferating endothelial cells. This model allowed us to test the role of endothelial proliferation on tumor growth, on its own and in combination with other treatments. Elimination of endothelial proliferation, radiation, or bevacizumab increased animal survival. To our surprise, by combining the elimination of endothelial proliferation with either of the other two treatments, we obtained a reduced survival response. Bevacizumab is thought to act through vessel normalization, and glioma irradiation requires adequate tissue oxygenation, to reduce tumor growth. Our results show formally that, in our model, intact tumor blood vessels are necessary for the antitumor effects of bevacizumab and radiotherapy. The clinical implications of our results suggest that the status of tumor vascularization is an important parameter to consider when evaluating tumor responses to potentially vessel-disrupting agents.
Immunohistochemistry and Hematoxylin-Eosin Staining
Immunohistochemistry (IHC) and hematoxylin and eosin (H&E) staining was performed on vibratome and paraffin brain sections of mice treated with phosphate buffered saline (PBS), ganciclovir (GCV), ionizing radiation (IR), IR+GCV, VEGF, and VEGF+GCV. IHC and H&E protocols can be found in the Supplementary material.
Ganciclovir Administration
NP tumor bearing Tie2-TK mice were treated twice daily with 25 mg/kg of the prodrug, GCV (Boitang, cat # RG001) or PBS via intraperitoneal injection. 21 Injections were performed from day 4 to 11 post tumor implantation.
Anti-VEGF Therapy
NP tumor implanted mice were treated with mouse anti-VEGF antibody (Genentech #5563) on days −1, 2, 5, 8, 11, 14, and 17 at a dose of 40 mg/kg i.p.
Radiation Treatment
Five days post implantation, Tie2-TK mice were irradiated with 20 Gy IR (2 Gy/day for 10 days).
Quantification of Immune Infiltration
The following groups were quantified for the detection of immune infiltration: PBS, GCV, IR, IR+GCV. Immune infiltration was made up of neutrophil nests, which were composed of >90% neutrophils, as determined by a pathologist (H.A.). Immune infiltration (ie, neutrophil nests) were quantified using ImageJ from images taken randomly from each tumor. A mean of 13 images per tumor were used, and we analyzed 2-5 tumors per group.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7. Data were analyzed with a Student's t-test or ANOVA as specified in Fig. legends . Data are represented as mean ± SEM. Values were considered significant at P ≤ 0.05. Kaplan-Meier survival curves were analyzed using the Mantel-Cox log-rank method.
Results
Characterization of Anti-Angiogenesis in a Tie2-TK Glioma Model Tie2-TK mice were genetically engineered to express the conditionally cytotoxic gene thymidine kinase from herpes simplex virus type 1 thymidine kinase (HSV1-TK) under the transcriptional control of the endothelial Tie2 promoter. This promoter was also linked to green fluorescent protein (GFP) by an internal ribosomal entry site (IRES) element (Fig. 1A) . In these mice, Tie2-positive TK-expressing proliferative endothelial cells were selectively killed by the administration of GCV (Fig. 1B) . TK converts GCV to GCV triphosphate, a purine analog that inhibits DNA replication selectively in proliferating Tie2-positive cells and leads to their apoptosis (Fig. 1B) . IHC demonstrates that tumor vessels from Tie2-TK mice are positive for GFP and express cluster of differentiation (CD)31 (Fig. 1C) . Co-localization confirms TK expression specifically in endothelial cells. Endogenous GFP expression from the Tie2 promoter and IRES is not strong enough alone to be detected without IHC (Fig. 1C3) . GFP expression within the blood vessels co-localized with CD31 expression demonstrated at lowpower (Fig. 1C4 ) and high-power (Fig. 1C5 ) merged images. We also examined the invasion pattern of NP tumors in an intracranial orthotopic model established in Tie2-TK mice. Confocal imaging of CD31 expression revealed that NP tumor cells (shown in green) were associated with the blood vessels (shown in red) at the invasive tumor border, as indicated by white arrowheads ( Fig. 1D1 and D2 ).
GCV Treatment Impairs Tumor Induced Angiogenesis in Tie2-TK Mice
We hypothesized that GCV treatment of Tie2-TK mice bearing NP tumors would result in reduction of neoangiogenesis. We analyzed blood vessel morphology and density across the tumors among 4 treatment groups (IR alone, GCV alone, IR+GCV, and PBS). Microscopic analysis revealed the presence of avascular regions within the center of GCV treated tumors (Fig. 2A5, A6 , and A7). We also observed reduced blood vessel density in the IR+GCV treated group (Fig. 2A13, A14 , and A15). Blood vessel density within the center of the tumor in PBS and IR treated mice was not affected (Fig. 2A1 , A2, A3, and A9, A10, A11). No differences were observed in vessel density at the tumor periphery (Fig. 2A4 , A8, A12, and A16). ImageJ quantification of CD31 expression demonstrated a statistically significant reduction in blood vessel density at the tumor core in GCV treated (**P < 0.048) and IR+GCV (**P < 0.05) treated mice ( Fig. 2B2 and B4 ). However, there was no significant difference in blood vessel density from tumor core to tumor border in PBS or IR treated mice ( Fig. 2B1 and B3 ).
Direct Blood Vessel Killing Prolongs Survival of Glioma-Bearing Tie2-TK Mice
Inhibition of tumor angiogenesis with anti-VEGF therapy has failed to increase glioma patient survival in phase III trials. 13, 22 Therefore, we wanted to determine if disrupting the proliferation of tumor vasculature through direct vessel cytotoxicity (ie, Tie2-HSV1-TK mice + GCV), alone or in combination with radiotherapy or anti-VEGF therapy, prolongs survival (Fig. 3A) . Kaplan-Meier survival analysis was performed for 4 treatment groups: PBS, GCV, IR, and GCV+IR (Fig. 3B ). The mice in the GCV treatment group exhibited increased median survival compared with the PBS group (OS: PBS = 12 vs GCV = 18 days, **P ≤ 0.001) ( indicates that GCV-mediated killing of proliferating endothelial cells attenuates the efficacy of IR sensitivity on NP tumor progression in Tie2-TK mice.
Histopathologic analysis of tumors from these treatment groups revealed that tumors from GCV treated mice had large necrotic regions with invasion of polymorphonuclear GCV and IR treatment alone significantly increases survival relative to PBS control. Median survival for PBS treated mice was 12 days, and for GCV and radiation treated mice 18 (**P < 0.001) and 25 (**P < 0.001) days, respectively. Median survival for GCV plus radiation treated mice was 18 days (**P < 0.001). (C) Histology is H&E staining of paraffin embedded sections from PBS, GCV, radiation, and GCV+radiation treated mice. Vessels with enlarged lumen and endothelial thinning were present in the GCV and IR+GCV groups. (D) Fluorescence scanning confocal micrographs of vibratome-cut brain sections of GFP expressing NP tumor cells (in green) implanted into mice treated with PBS, GCV, radiation, or GCV+ radiation. Sections from GCV treated mice have more necrosis relative to the PBS treated (white and yellow arrowheads). At higher magnification, there are a greater number of rounds, dying tumor cells indicated with thick white arrowheads. (E) Immunohistochemistry on sections of NP tumor-bearing Tie2-TK mice treated with PBS, GCV, IR, or IR+GCV with an antibody against hypoxia marker, HIF-1α. HIF-1α-positive hypoxic areas were marked with dotted white line in GCV and IR+GCV treated groups. (F) Inflammation (leukocyte infiltration) was evaluated in H&E stained sections from PBS, GCV, IR, and IR+GCV treated mice. The area occupied by neutrophil and leukocyte nests in IR and IR+GCV are indicated by red dotted lines in Fig. 3F . Areas occupied by infiltrating leukocytes were quantified using ImageJ software. Bar graphs (Fig. 3F , righthand side) represent the total area of infiltrating leukocytes in each group. The area occupied by infiltrating leukocyte nests was highest in IR (**P < 0.0016, IR vs PBS; *P < 0.024, IR vs GCV; *P < 0.024 IR vs IR+GCV). Statistical evaluation was performed using a one-way ANOVA, followed by a posterior multiple comparison test, corrected for multiple comparisons by controlling the false discovery rate using the 2-stage step-up method of Benjamin, Krieger, and Yekutieli using the PRISM software. Nonsignificant = n.s. Error bars = mean ± SEM. cells compared with PBS treatment (Fig. 3C4 and C5) . Furthermore, blood vessels in GCV or GCV+IR treated mice displayed enlarged lumina and thinning of endothelial cells, likely leading to vessel leakiness. Blood vessels in PBS and IR treated groups appeared intact ( Fig. 3C6 and  C12 ). Tumors of GCV treated mice displayed extensive necrotic areas, mainly within the tumor centers (Fig. 3D) . High power images of the necrotic areas demonstrated an abundance of dying round-shaped tumor cells, as indicated by white arrowheads in (Fig. 3D6 and D12) . Tumors from PBS treated mice or IR alone did not exhibit necrosis (Fig. 3D1,  D3 , and D7). We next compared the pattern of HIF-1α immunoreactivity in each group by IHC. GCV and IR+GCV treated groups showed highest levels of HIF-1α immunoreactivity; in the GCV group the distribution was centered around the tumor periphery, while in the GCV+IR group it was centrally located (Fig. 3E ). Higher expression of HIF-1α in the IR+GCV group compared with IR alone suggests that activation of the HSV1-TK system disrupts the tumor blood supply, thereby reducing tumor oxygenation, stimulating expression of HIF-1α, and thus reducing sensitivity to radiation. We further investigated the extent of inflammation (mostly polymorphonuclear infiltration) in brain sections from moribund mice (Fig. 3F ). ImageJ analysis revealed that polymorphonuclear cells were significantly increased in the IR group compared with all other groups. Mice treated with GCV or IR+GCV had significantly reduced numbers of infiltrating polymorphonuclear cells compared with IR treated mice. Lower infiltration of inflammatory cells in the IR+GCV group suggests that GCV-mediated killing of proliferating endothelial cells reduces inflammatory infiltration, which could contribute to reducing the effects of IR therapy.
NeuroOncology
Endothelial Cell Death Increases Tumor Cell Apoptosis and Reduces Tumor Proliferation
GCV treatment blocked angiogenesis by disrupting reactive blood vessels, as shown in Fig. 3 . We further investigated the effect of GCV treatment on the proliferation of tumor cells. Ki67 expression was assessed in PBS, GCV, IR, and GCV+IR treatment groups. Analysis revealed a lower Ki67 index in GCV (Fig. 4A4 to A6) , IR (Fig. 4A7 to A9 ), and IR+GCV ( Fig. 4A10 to A12 ) treatment groups within the tumor core compared with the PBS group (Fig. 4A1 and A3) , as indicated by the white arrowheads. Tumor cell proliferation at the tumor border was not affected by GCV treatment (data not shown). Total Ki67-positive cells were significantly lower in GCV (***P < 0.0003), IR (***P < 0.0002), and IR+GCV (***P < 0.0027) groups relative to the PBS treatment group (Fig. 4B) . Decreased Ki67-positive cells in GCV and GCV+IR treatment groups correlated with increased survival of Tie2-TK mice implanted with NP tumors.
GCV-Mediated Killing of Proliferating Endothelial Cells Enhances Cleaved Caspase-3 Immunoreactivity
We analyzed brains from moribund mice treated with PBS, GCV, IR, or GCV+IR for expression of cleaved caspase-3 (CC3), a marker of apoptosis. The tumor cells from animals treated with GCV (Fig. 5A3 to A6), IR (Fig. 5A7 to A9 ), or GCV+IR (Fig. 5A10 to A12 ) exhibited extensive apoptosis within the center of the tumor compared with PBS treatment (Fig. 5A1 to A3 ). The tumor border for all 4 treatment conditions did not demonstrate CC3 positivity (data not shown). Quantification of the total number of CC3-positive cells in each treatment group revealed that tumors from mice treated with either GCV (***P < 0.0001), IR (***P < 0.0001), or GCV+IR (***P < 0.0005) had significantly higher CC3-positive tumor cells compared with the PBS control (Fig. 5B) . However, NP tumor bearing mice treated with IR+GCV had a lower number of CC3-positive cells compared with IR alone (Fig. 5B) . The increased number of CC3-positive cells in the GCV and IR treatment groups correlates with increased survival.
GCV-Mediated Killing of Proliferating Endothelial Cells Attenuates the Efficacy of Anti-VEGF Therapy
To determine whether inhibition of proliferating vascular endothelium can increase the efficacy of anti-VEGF therapy, we studied the effect of combination anti-VEGF and GCV treatments on the OS of NP tumor bearing Tie2-TK mice. We treated 4 groups (n = 4/group) of NP tumor implanted Tie2-TK mice with (i) PBS (control), (ii) GCV, (iii) anti-VEGF antibodies, and (iv) GCV+anti-VEGF antibody and monitored tumor progression (Fig. 6A) . GCV therapy alone significantly increased the survival of tumor bearing Tie2-TK mice (OS: GCV = 18 days) (Fig. 3B) . Treatment with anti-VEGF antibodies alone extended the median OS of NP tumor bearing mice (OS: anti-VEGF = 25 days) compared with control (OS: PBS = 13 days) (Fig. 6B) . However, mice treated with combined anti-VEGF plus GCV resulted in lower median survival compared with anti-VEGF antibody alone (OS: anti-VEGF = 25 vs anti-VEGF+GCV = 19 days) (Fig. 6B) . Given the significant improvement in survival observed in mice treated with anti-VEGF therapy alone, but not with dual anti-VEGF plus GCV therapy, this prompted us to investigate the tumor vascular integrity and normalization in these treatment groups. CD31 IHC staining was performed for each treatment group. Microscopic analysis revealed that PBS treated tumors had increased angiogenesis. As previously demonstrated, GCV treated mice had a significant decrease in vessel density, with the most pronounced effect at the center of the tumor (Fig. 6C4 to C6 ). Tumors from mice treated with anti-VEGF therapy displayed a high density of intact and pathological blood vessels, suggesting a greater extent of vessel normalization after anti-VEGF therapy (Fig. 6C7 to C9 ). Blood vessel morphology in dual GCV and anti-VEGF therapy treated mice was disrupted and vessel normalization was not observed (Fig. 6C10 to C12 ). Low blood vessel density was observed in tumors of mice that received GCV treatment alone or in combination with anti-VEGF therapy. These data suggest that GCV-mediated killing of proliferating endothelial cells limits the efficacy of anti-VEGF treatment.
Discussion
Neoangiogenesis is a central biological process for glioma progression. Inhibiting the tumor blood supply is an
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attractive therapeutic strategy. Bevacizumab is a monoclonal antibody that binds VEGF and is the most comprehensively studied anti-angiogenic therapy for the treatment of glioma. Clinical trials indicate that bevacizumab extends PFS in patients with primary gliomas. 13, 14 However, multiple phase III randomized controlled trials failed to demonstrate improved OS. 12-14,23, 24 The basis of bevacizumab's mechanism of action, the role of tumor neoangiogenesis on tumor progression, and the mechanisms of resistance to bevacizumab are only partially understood. We examined the effects of bevacizumab and irradiation in a transgenic model of inducible elimination of proliferating endothelial cells. In this model, elimination of proliferating endothelial cells reduced the efficacy of both treatments. Several mechanisms have been proposed to explain the resistance to anti-VEGF therapy in glioma patients. Recruitment of vascular progenitors such as Tie2-positive monocytes from the bone marrow and activation of Tie2/ angiopoietin 2 25 pathways are associated with resistance to bevacizumab. 26 We have targeted VEGF independent mechanisms of angiogenesis by using a transgenic GBM mouse model with inducible, selective ablation of proliferating vascular endothelial cells. In this model, HSV1-TK is selectively expressed in vascular endothelium under transcriptional control of the Tie2 promoter. Administration of GCV leads to cytotoxic activity of TK and selective killing of proliferating endothelial cells.
Our data demonstrate that elimination of neoangiogenesis decreases tumor growth and prolongs animal survival. In these mice, tumor necrosis is more abundant in the center of the tumor, likely due to hypoxia and impaired angiogenesis caused by HSV1-TK. Further, our data demonstrate that there is a reduction in tumor cell proliferation and an increase in caspase-3 mediated apoptosis. A study by De Palma et al 18 demonstrates that GCV-mediated elimination of Tie2 expressing monocytes reduced tumor angiogenesis and tumor growth in N202 tumors implanted subcutaneously in mice. 18 However, this study did not evaluate the effect of TK-GCV on the antitumor efficacy of radiation and anti-VEGF therapy.
We also demonstrate that targeting Tie2-TK expressing cells preferentially eliminates endothelial cells from the center of the tumor. Hypoxic conditions are more prevalent in the tumor center, leading to increased activation and proliferation of endothelial cells and increased cell death upon administration of GCV. As per our 6 and others' 27 previous data, tumor cells toward the periphery are mainly located along remaining intact blood vessels. Radiosensitivity of tumor cells is determined in part by the concentration of dissolved tissue oxygen and reduction reactive oxygen species. 28 In our experiments, radiation therapy alone improved survival. However, activation of the HSV1-TK system counteracted the therapeutic effects of radiation. We demonstrate that activation of the HSV1-TK system disrupts the tumor blood supply, thereby reducing tumor oxygenation and sensitivity to radiation. This is consistent with recent phase III trials (AVAglio and RTOG 0825) in which no increased OS was observed when bevacizumab was combined with radiation therapy. 13, 14 Although the direct inhibition of proliferating endothelial cells prolongs survival in this in vivo glioma model, it fails to induce complete growth arrest and tumor regression. This suggests that tumor progression occurs independently of angiogenesis. We and others have previously demonstrated that glioma cell growth and invasion occur by vessel co-option and perivascular invasion. 6, 29 The subjugation of the native blood supply of adjacent normal parenchyma may also be an escape mechanism by which a growing tumor evades anti-angiogenic therapy. This mechanism is independent of the inhibition of neoangiogenesis attributed to anti-VEGF therapy or by selective ablation of proliferating vascular endothelium as we have done in the Tie2-TK mice. In our model, the elimination of reactive blood vessels, contrary to our predictions, reduced the efficacy of anti-VEGF therapy. This may indicate that intact blood vessels and the induction of vessel normalization are necessary conditions for bevacizumab's therapeutic effect. Irradiation is known to increase the influx of inflammatory cells into tumors. 17, 30 Stimulation of inflammatory cell influx is likely to have an inhibitory effect on tumor growth. It is thus possible that GCV-mediated killing of proliferating endothelial cells may reduce the entry of inflammatory cells into tumors. Indeed, IR treated mice have the highest amount of infiltrating polymorphonuclear cells, and the highest survival. Treating these animals with GCV reduces both inflammatory infiltration and survival. GCV-mediated killing of proliferating endothelial cells may, at least in part, inhibit the therapeutic effect of radiation therapy. In summary, treatment of a murine glioma implanted into transgenic mice (expressing HSV1-TK in endothelial cells and precursors) with (i) GCV, (ii) anti-VEGF antibodies, or (iii) radiation prolongs animal survival. If, however, GCV and bevacizumab, or GCV and radiation, are administered concurrently, GCV-mediated killing of proliferating endothelial cells reduces the efficacy (ie, survival) of anti-VEGF therapy or radiation. These findings suggest that in our model intact blood vessels are necessary for full therapeutic efficacy of anti-VEGF and radiation. Whether in human patients the efficacy of anti-VEGF antibodies or radiation treatment is also dependent on the presence of intact blood vessels remains to be determined. Equally, whether any treatment (ie, radiation or temozolomide) that induces devascularization can inhibit later treatment with bevacizumab also requires further investigation.
Supplementary Material
Supplementary material is available at Neuro-Oncology online.
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